Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.36 (4.24%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £561.06m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Total Voting Rights

16 May 2012 11:11

RNS Number : 4584D
Allergy Therapeutics PLC
16 May 2012
 



16 May 2012

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Total Voting Rights

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces that the Company's share capital consists of 406,912,981 Ordinary 0.1p shares with voting rights attached (one vote per Ordinary share). The Company has no shares in Treasury therefore the total number of voting rights in Allergy Therapeutics is 406,912,981.

 

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FSA's Disclosure and Transparency Rules.

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Clare Terlouw/ Christopher Golden

FTI Consulting

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAESKFESAEFF
Date   Source Headline
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)
16th Oct 20235:39 pmRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
16th Oct 20233:03 pmRNSHolding(s) in Company
16th Oct 20232:42 pmRNSForm 8.5 (EPT/RI)
16th Oct 202312:42 pmRNSForm 8.5 (EPT/NON-RI)
16th Oct 202311:17 amRNSForm 8 (DD) - Allergy Therapeutics plc
16th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
16th Oct 20238:01 amRNSUnconditional Mandatory Cash Offer
13th Oct 20237:00 amRNSResult of Open Offer and Subscription
12th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
11th Oct 20238:35 amRNSForm 8.5 (EPT/RI)
10th Oct 20238:13 amRNSForm 8.5 (EPT/RI)
9th Oct 20238:44 amRNSForm 8.5 (EPT/RI)
5th Oct 20238:42 amRNSForm 8.5 (EPT/RI)
4th Oct 20238:42 amRNSForm 8.5 (EPT/RI)
3rd Oct 20238:16 amRNSForm 8.5 (EPT/RI)
2nd Oct 20235:53 pmRNSBlock Listing Interim Review
2nd Oct 20239:36 amRNSForm 8.5 (EPT/RI)
29th Sep 20239:19 amRNSForm 8.5 (EPT/RI)
29th Sep 20238:46 amRNSForm 8.5 (EPT/NON-RI)
28th Sep 20238:52 amRNSForm 8.5 (EPT/RI)
27th Sep 202312:04 pmRNSPublication of Open Offer Circular – Amendment
27th Sep 202310:45 amRNSForm 8.5 (EPT/NON-RI)
27th Sep 20237:01 amRNSPublication of Open Offer Circular
27th Sep 20237:00 amRNSUnaudited Preliminary Results 2023
26th Sep 20238:36 amRNSForm 8.5 (EPT/RI)
26th Sep 20237:00 amRNSPhase I VLP Peanut PROTECT trial progress
25th Sep 20239:07 amRNSForm 8.5 (EPT/RI)
22nd Sep 20239:59 amRNSForm 8.5 (EPT/NON-RI)
22nd Sep 20237:35 amRNSForm 8.5 (EPT/RI)
22nd Sep 20237:00 amRNSSatisfaction of FDI clearance conditions
21st Sep 202310:34 amRNSForm 8.5 (EPT/NON-RI)
21st Sep 20238:13 amRNSForm 8.5 (EPT/RI)
18th Sep 20238:16 amRNSForm 8.5 (EPT/RI)
15th Sep 20233:14 pmRNSForm 8.5 (EPT/NON-RI)
15th Sep 20239:02 amRNSForm 8.5 (EPT/RI)
14th Sep 20237:33 amRNSForm 8.5 (EPT/RI)
13th Sep 20237:39 amRNSForm 8.5 (EPT/RI)
12th Sep 20237:00 amRNSForm 8.5 (EPT/RI)
11th Sep 20231:01 pmRNSForm 8.5 (EPT/RI)
8th Sep 20238:57 amRNSForm 8.5 (EPT/RI)
7th Sep 20238:38 amRNSForm 8.5 (EPT/RI)
6th Sep 20238:45 amRNSForm 8.5 (EPT/RI)
5th Sep 202311:24 amRNSForm 8 (DD)
5th Sep 20238:22 amRNSForm 8.5 (EPT/RI)
1st Sep 20238:01 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.